- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05629234
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) (ROSY-T)
ROSY-T: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100142
- Research Site
-
Chongqing, China, 400042
- Research Site
-
Shanghai, China, 200433
- Research Site
-
Yangzhou, China, 225001
- Research Site
-
Zhengzhou, China, 450008
- Research Site
-
-
-
-
-
Villejuif Cedex, France, 94805
- Research Site
-
-
-
-
-
Cheongju-si, Korea, Republic of, 28644
- Research Site
-
Dong-gu, Korea, Republic of, 44033
- Research Site
-
Goyang-si, Korea, Republic of, 10408
- Research Site
-
Seongnam-si, Korea, Republic of, 13620
- Research Site
-
Seoul, Korea, Republic of, 03722
- Research Site
-
Seoul, Korea, Republic of, 03080
- Research Site
-
Seoul, Korea, Republic of, 06351
- Research Site
-
Seoul, Korea, Republic of, 06591
- Research Site
-
Seoul, Korea, Republic of, 5505
- Research Site
-
-
-
-
-
Georgetown, Malaysia, 10450
- Research Site
-
Johor Bahru, Malaysia, 81100
- Research Site
-
Kuantan, Malaysia, 25100
- Research Site
-
Kuching, Malaysia, 93586
- Research Site
-
-
-
-
-
Szczecin, Poland, 70-419
- Research Site
-
-
-
-
-
Kaohsiung, Taiwan, 83301
- Research Site
-
Taichung, Taiwan, 40705
- Research Site
-
Tainan, Taiwan, 736
- Research Site
-
Tainan, Taiwan, 704
- Research Site
-
Taipei, Taiwan, 112201
- Research Site
-
Taoyuan, Taiwan, 333
- Research Site
-
-
-
-
-
Nottingham, United Kingdom, NG5 1PB
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provision of signed and dated, written Informed Consent Form (ICF).
- Patient is currently deriving clinical benefit from continued treatment with osimertinib in an AstraZeneca parent study using osimertinib monotherapy which has met its endpoints or has otherwise stopped.
- Patients should be using adequate contraceptive measures.
Exclusion Criteria:
- Ongoing, unresolved, Grade 3 or above toxicity requiring interruption of treatment at the time of the termination of the parent study.
- Currently receiving treatment with any prohibited medication(s).
- Concurrently enrolled in any other type of medical research judged not to be scientifically, or medically compatible with this study.
- Permanent discontinuation from the parent study due to toxicity or disease progression.
- Local access to commercially-available drug at no cost to the patient is permitted by local regulation.
Exclusion Criteria for the sub-study:
1. Active infection including active hepatitis C and Human immunodeficiency virus (HIV) infection or active uncontrolled Hepatitis B virus (HBV) infection. Screening for chronic conditions is not required.
Patients with HBV infection are only eligible if they meet all the following criteria:
- Demonstrated absence of HCV co-infection or history of HCV co-infection;
- Demonstrated absence of HIV infection;
- Patients receiving anti-viral treatment for at least 6 weeks prior to study treatment, HBV DNA is suppressed to < 100 IU/mL, and transaminase levels are below ULN.
Patients with a resolved or chronic HBV infection are eligible if they are:
- Negative for HBsAg and positive for anti-HBc IgG. In addition, patients must be receiving anti-viral prophylaxis for 2 to 4 weeks prior to study treatment and 6 to 12 months (to be determined by hepatologist) post treatment; or
- Positive for HBsAg, but for > 6 months have had transaminases levels below ULN and HBV DNA levels below < 100 IU/mL (ie, patients are in an inactive carrier state). In addition, patients must be receiving anti-viral prophylaxis for 2 to 4 weeks prior to study treatment.
Should participants with HIV infection be included, patients are only eligible if they meet all the following criteria:
- Undetectable viral RNA load for 6 months
- CD4+ count of > 350 cells/μL
- No history of AIDS-defining opportunistic infection within the past 12 months (to be determined by hepatologist) post treatment
- Stable for at least 4 weeks on anti-HIV medications.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Osimertinib
Participants will receive Osimertinib
|
Osimertinib (dose range of 40 mg to 240 mg orally, once daily)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)
Time Frame: Until 90 days after the last dose of study treatment
|
Safety and tolerability of osimertinib will be assessed.
|
Until 90 days after the last dose of study treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D5161N00007
- 2022-001447-24 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for individual participant data (IPD), but this does not mean all requests will be shared.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
University of Wisconsin, MadisonCompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy Subject | Stage I Colorectal Cancer | Stage IIIA Colorectal Cancer | Stage IIIB Colorectal Cancer | Stage... and other conditionsUnited States
Clinical Trials on Osimertinib
-
Li ZhangHubei Cancer HospitalNot yet recruitingStage IV Non-small Cell Lung CancerChina
-
Qingdao Central HospitalRecruiting
-
Wuhan Union Hospital, ChinaNot yet recruitingNon Small Cell Lung Cancer
-
AstraZenecaActive, not recruitingNon Small Cell Lung Cancer (Stage III)United States, Spain, Taiwan, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Hungary, India, Japan, Mexico, Peru, Russian Federation, China, Malaysia, Argentina
-
AstraZenecaTerminated
-
Istituto Oncologico Veneto IRCCSActive, not recruitingEGF-R Positive Non-Small Cell Lung CancerItaly
-
Shanghai JMT-Bio Inc.CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingLocally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations
-
Qingdao Central HospitalRecruiting
-
AstraZenecaCompletedT790M Positive NSCLC PatientsChina
-
Sun Yat-sen UniversityUnknownNon-small Cell Lung CancerChina